VivaBioCell

VivaBioCell is a biotechnology startup headquartered in Italy, focusing on developing, manufacturing, and commercializing automated solutions for the manufacturing of advanced therapy medicinal products. The company, founded in 2007, has roots as a university spin-off and has since grown, with the acquisition by ImmunityBio Inc. (formerly NantCell Inc.) in 2015. This acquisition brought valuable assets to the company, including a multidisciplinary team with deep and diversified knowledge and enduring partnerships with clinical and technology stakeholders. VivaBioCell's mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing. Its systems and commitment to customer support enable a safe and seamless conversion of manual protocols into highly standardized scalable processes, focusing on risk reduction and cost containment while maintaining regulatory and quality requirements. The company received a €440.00K Seed Round investment on 12 July 2007 from investors Generali Horizon, Banca Popolare di Cividale, and Friulia SGR. VivaBioCell aims to inspire the application and diffusion of sustainable advanced therapies with the vision of bridging regenerative medicine into the worldwide clinical practice. With its strong foundation, strategic partnerships, and commitment to innovation, VivaBioCell is poised for further growth and success in the biotechnology industry.